Tumor Classification Reference

<a class="glossaryLink" aria-describedby="tt" data-cmtooltip="<div class=glossaryItemTitle>Tumor</div><div class=glossaryItemBody>&lt;p&gt;&lt;strong data-start=&quot;50&quot; data-end=&quot;64&quot;&gt;Definition: &lt;/strong&gt;A &lt;strong data-start=&quot;69&quot; data-end=&quot;78&quot;&gt;tumor&lt;/strong&gt; is an abnormal mass of tissue resulting from uncontrolled, excessive cell proliferation. Tumors can be &lt;strong data-start=&quot;182&quot; data-end=&quot;192&quot;&gt;benign&lt;/strong&gt; (non-cancerous) or &lt;strong data-start=&quot;212&quot; data-end=&quot;225&quot;&gt;malignant&lt;/strong&gt; (cancerous).&lt;/p&gt; &lt;p&gt;&lt;strong data-start=&quot;249&quot; data-end=&quot;268&quot;&gt;Types of Tumors&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;div class=&quot;su-table su-table-alternate&quot;&gt;&lt;/p&gt; &lt;div class=&quot;_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse&quot;&gt; &lt;table class=&quot;w-fit min-w-(--thread-content-width)&quot; data-start=&quot;270&quot; data-end=&quot;761&quot;&gt; &lt;thead data-start=&quot;270&quot; data-end=&quot;378&quot;&gt; &lt;tr data-start=&quot;270&quot; data-end=&quot;378&quot;&gt; &lt;th data-start=&quot;270&quot; data-end=&quot;284&quot; data-col-size=&quot;sm&quot;&gt;Type&lt;/th&gt; &lt;th data-start=&quot;284&quot; data-end=&quot;331&quot; data-col-size=&quot;md&quot;&gt;Characteristics&lt;/th&gt; &lt;th data-start=&quot;331&quot; data-end=&quot;378&quot; data-col-size=&quot;md&quot;&gt;Behavior&lt;/th&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody data-start=&quot;487&quot; data-end=&quot;761&quot;&gt; &lt;tr data-start=&quot;487&quot; data-end=&quot;611&quot;&gt; &lt;td data-start=&quot;487&quot; data-end=&quot;501&quot; data-col-size=&quot;sm&quot;&gt;&lt;strong data-start=&quot;489&quot; data-end=&quot;499&quot;&gt;Benign&lt;/strong&gt;&lt;/td&gt; &lt;td data-col-size=&quot;md&quot; data-start=&quot;501&quot; data-end=&quot;565&quot;&gt;Well-differentiated, slow growing, encapsulated, non-invasive&lt;/td&gt; &lt;td data-col-size=&quot;md&quot; data-start=&quot;565&quot; data-end=&quot;611&quot;&gt;Usually localized, rarely life-threatening&lt;/td&gt; &lt;/tr&gt; &lt;tr data-start=&quot;612&quot; data-end=&quot;761&quot;&gt; &lt;td data-start=&quot;612&quot; data-end=&quot;637&quot; data-col-size=&quot;sm&quot;&gt;&lt;strong data-start=&quot;614&quot; data-end=&quot;627&quot;&gt;Malignant&lt;/strong&gt; (Cancer)&lt;/td&gt; &lt;td data-col-size=&quot;md&quot; data-start=&quot;637&quot; data-end=&quot;711&quot;&gt;Poorly differentiated, rapid growth, invasive, potential to metastasize&lt;/td&gt; &lt;td data-col-size=&quot;md&quot; data-start=&quot;711&quot; data-end=&quot;761&quot;&gt;Can invade nearby tissues and spread distantly&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt; &lt;/div&gt; &lt;div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div tabindex=&quot;-1&quot;&gt; &lt;/div&gt; &lt;div class=&quot;_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse&quot; tabindex=&quot;-1&quot;&gt;&lt;strong data-start=&quot;772&quot; data-end=&quot;788&quot;&gt;Key Concepts&lt;/strong&gt;&lt;/div&gt; &lt;ul data-start=&quot;790&quot; data-end=&quot;1179&quot;&gt; &lt;li data-start=&quot;790&quot; data-end=&quot;874&quot;&gt;&lt;strong data-start=&quot;792&quot; data-end=&quot;804&quot;&gt;Neoplasm&lt;/strong&gt;: Another term for tumor; refers to new and abnormal growth of tissue.&lt;/li&gt; &lt;li data-start=&quot;875&quot; data-end=&quot;929&quot;&gt;&lt;strong data-start=&quot;877&quot; data-end=&quot;890&quot;&gt;Carcinoma&lt;/strong&gt;: Malignant tumor of epithelial origin.&lt;/li&gt; &lt;li data-start=&quot;930&quot; data-end=&quot;989&quot;&gt;&lt;strong data-start=&quot;932&quot; data-end=&quot;943&quot;&gt;Sarcoma&lt;/strong&gt;: Malignant tumor of connective tissue origin.&lt;/li&gt; &lt;li data-start=&quot;990&quot; data-end=&quot;1076&quot;&gt;&lt;strong data-start=&quot;992&quot; data-end=&quot;1006&quot;&gt;Metastasis&lt;/strong&gt;: Spread of malignant tumor cells from primary site to distant organs.&lt;/li&gt; &lt;li data-start=&quot;1077&quot; data-end=&quot;1179&quot;&gt;&lt;strong data-start=&quot;1079&quot; data-end=&quot;1105&quot;&gt;Tumor Microenvironment&lt;/strong&gt;: Surrounding cells, blood vessels, immune cells influencing tumor growth.&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong data-start=&quot;1190&quot; data-end=&quot;1224&quot;&gt;Clinical Relevance in Pharmacy&lt;/strong&gt;&lt;/p&gt; &lt;ul data-start=&quot;1226&quot; data-end=&quot;1464&quot;&gt; &lt;li data-start=&quot;1226&quot; data-end=&quot;1284&quot;&gt;Tumor type, grade, and stage influence treatment choice.&lt;/li&gt; &lt;li data-start=&quot;1285&quot; data-end=&quot;1391&quot;&gt;Pharmacists must understand tumor biology to optimize chemotherapy, targeted therapy, and immunotherapy.&lt;/li&gt; &lt;li data-start=&quot;1392&quot; data-end=&quot;1464&quot;&gt;Tumor markers may be used to monitor disease or response to treatment.&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong data-start=&quot;1475&quot; data-end=&quot;1494&quot;&gt;Practice Pearls&lt;/strong&gt;&lt;/p&gt; &lt;ul data-start=&quot;1496&quot; data-end=&quot;1714&quot;&gt; &lt;li data-start=&quot;1496&quot; data-end=&quot;1577&quot;&gt;Distinguish benign from malignant to understand urgency and treatment approach.&lt;/li&gt; &lt;li data-start=&quot;1578&quot; data-end=&quot;1635&quot;&gt;Know common tumor types relevant to your practice area.&lt;/li&gt; &lt;li data-start=&quot;1636&quot; data-end=&quot;1714&quot;&gt;Stay updated on tumor-specific targeted therapies and resistance mechanisms.&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong data-start=&quot;1721&quot; data-end=&quot;1738&quot;&gt;Key Takeaway:&lt;/strong&gt;&lt;<a class="glossaryLink" aria-describedby="tt" data-cmtooltip="<div class=glossaryItemTitle>BR Regimen</div><div class=glossaryItemBody>&lt;p&gt;&lt;strong&gt;Indication:&lt;/strong&gt;&lt;/p&gt; &lt;ul data-start=&quot;236&quot; data-end=&quot;358&quot;&gt; &lt;li data-start=&quot;236&quot; data-end=&quot;309&quot;&gt;Indolent B-cell NHL (e.g., follicular lymphoma), mantle cell lymphoma&lt;/li&gt; &lt;li data-start=&quot;310&quot; data-end=&quot;358&quot;&gt;Often used in frontline or relapsed settings&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;Agents:&lt;/strong&gt;&lt;/p&gt; &lt;ul data-start=&quot;374&quot; data-end=&quot;489&quot;&gt; &lt;li data-start=&quot;374&quot; data-end=&quot;440&quot;&gt;Bendamustine: Alkylating agent with purine analog activity&lt;/li&gt; &lt;li data-start=&quot;441&quot; data-end=&quot;489&quot;&gt;Rituximab: Anti-CD20 monoclonal antibody&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;Dosing (Typical Schedule):&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;Cycle = 28 days; typically 6 cycles&lt;/p&gt; &lt;ul data-start=&quot;573&quot; data-end=&quot;726&quot;&gt; &lt;li data-start=&quot;573&quot; data-end=&quot;619&quot;&gt;Bendamustine: 90 mg/m² IV Days 1 and 2&lt;/li&gt; &lt;li data-start=&quot;620&quot; data-end=&quot;726&quot;&gt;Rituximab: 375 mg/m² IV Day 1 (can be moved to Day 0 to reduce infusion overlap with bendamustine)&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;Key Pharmacist Considerations:&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Pre-medications:&lt;/strong&gt;&lt;/p&gt; &lt;ul data-start=&quot;796&quot; data-end=&quot;944&quot;&gt; &lt;li data-start=&quot;796&quot; data-end=&quot;884&quot;&gt;Rituximab: Acetaminophen, antihistamine, corticosteroid to reduce infusion reactions&lt;/li&gt; &lt;li data-start=&quot;885&quot; data-end=&quot;944&quot;&gt;Antiemetics for bendamustine (moderate emetogenic risk)&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;Infusion Reactions:&lt;/strong&gt;&lt;/p&gt; &lt;ul data-start=&quot;972&quot; data-end=&quot;1056&quot;&gt; &lt;li data-start=&quot;972&quot; data-end=&quot;1056&quot;&gt;Rituximab: Monitor closely during 1st infusion; slower rate and premeds required&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;Myelosuppression:&lt;/p&gt; &lt;ul data-start=&quot;1082&quot; data-end=&quot;1201&quot;&gt; &lt;li data-start=&quot;1082&quot; data-end=&quot;1140&quot;&gt;Common (especially neutropenia); monitor CBC regularly&lt;/li&gt; &lt;li data-start=&quot;1141&quot; data-end=&quot;1201&quot;&gt;Consider growth factor support depending on patient risk&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;Infection Risk:&lt;/strong&gt;&lt;/p&gt; &lt;ul data-start=&quot;1225&quot; data-end=&quot;1376&quot;&gt; &lt;li data-start=&quot;1225&quot; data-end=&quot;1301&quot;&gt;Risk of reactivation (HBV, PJP, VZV); screen for HBV before starting&lt;/li&gt; &lt;li data-start=&quot;1302&quot; data-end=&quot;1376&quot;&gt;Consider prophylaxis (e.g., antivirals, PJP prophylaxis based on risk)&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;Other Toxicities:&lt;/strong&gt;&lt;/p&gt; &lt;ul data-start=&quot;1402&quot; data-end=&quot;1543&quot;&gt; &lt;li data-start=&quot;1402&quot; data-end=&quot;1459&quot;&gt;Bendamustine: Rash, fatigue, electrolyte disturbances&lt;/li&gt; &lt;li data-start=&quot;1460&quot; data-end=&quot;1543&quot;&gt;Tumor lysis syndrome (TLS) risk in bulky disease—ensure hydration, monitor labs&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;Renal/Hepatic:&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&nbsp;&lt;/p&gt; &lt;ul data-start=&quot;1566&quot; data-end=&quot;1641&quot;&gt; &lt;li data-start=&quot;1566&quot; data-end=&quot;1641&quot;&gt;Adjust bendamustine in renal impairment; caution in hepatic dysfunction&lt;/li&gt; &lt;/ul&gt;</div><div class=cmtt_synonyms_wrapper><div class=cmtt_synonyms_title>Synonyms </div><div class=cmtt_synonyms>BR</div></div><div class=glossaryTooltipMoreLinkWrapper><a class=glossaryTooltipMoreLink href=https://imc.3jpharmainc.com/glossary/br-regimen/ target=_blank>Details Link</a></div>" href="https://imc.3jpharmainc.com/glossary/br-regimen/" target="_blank" data-gt-translate-attributes='[{"attribute":"data-cmtooltip", "format":"html"}]' tabindex='0' role='link'>br</a> data-start=&quot;1738&quot; data-end=&quot;1741&quot; /&gt; A tumor is an abnormal tissue growth that can be benign or malignant, with malignant tumors requiring targeted pharmacologic interventions based on tumor biology and clinical characteristics.&lt;/p&gt;</div><div class=glossaryTooltipMoreLinkWrapper><a class=glossaryTooltipMoreLink href=https://imc.3jpharmainc.com/glossary/tumor/ target=_blank>Details Link</a></div>" href="https://imc.3jpharmainc.com/glossary/tumor/" target="_blank" data-gt-translate-attributes='[{"attribute":"data-cmtooltip", "format":"html"}]' tabindex='0' role='link'>Tumor</a> Classification Reference
Click a node to select it
Label:
Color:
Tags: , , , ,